- Zomedica Corp. reported **record quarterly revenue** of **$8.1 million** for the third quarter ended September 30, 2025, marking a **16% increase** compared to the same period in the prior year and the **19th straight quarter** of year-over-year revenue growth.  **[1684144_0001654954-25-012575_zom_ex991.htm:0]** **[1684144_0001654954-25-012575_zom_ex991.htm:2]** 
- The company achieved a **gross margin of 67%** for the third quarter of 2025.  **[1684144_0001654954-25-012575_zom_ex991.htm:0]** **[1684144_0001654954-25-012575_zom_ex991.htm:2]** 
- Zomedica's **net loss decreased by 9%** to **$6.1 million** for Q3 2025, and its **Adjusted Non-GAAP EBITDA loss decreased by 14%** to **$3.7 million** compared to the third quarter of 2024.  **[1684144_0001654954-25-012575_zom_ex991.htm:2]** 
- As of September 30, 2025, Zomedica maintained **$54.4 million** in cash, cash equivalents, and available-for-sale securities.  **[1684144_0001654954-25-012575_zom_ex991.htm:2]** **[1684144_0001654954-25-012575_zom_ex991.htm:3]** 
- Total operating expenses for the quarter ended September 30, 2025, were **$12.0 million**, a **4% decrease** from the prior year, driven by a **$0.5 million reduction** in OPEX.  **[1684144_0001654954-25-012575_zom_ex991.htm:1]** **[1684144_0001654954-25-012575_zom_ex991.htm:2]**

Zomedica (ZOMDF)